Tag Archives: share issue

Dignitana

The Dignitana issue – and how I lost money

Facebooktwittergoogle_pluslinkedinmailFacebooktwittergoogle_pluslinkedinmail

The first week of 2018 has offered a sting of good news and along with the positive sentiments of the market has given a fantastic lift to the portfolio. I hope this will continue throughout the year! In an earlier post, I promised to tell about my mistakes and miscalculation around the Dignitana issue. This is a story much better told after some profitable days. Losing money is today’s theme – luckily, it was mine … not yours! Continue reading

Three reports in line with expectation – and slaughter of Dignitana

Facebooktwittergoogle_pluslinkedinmailFacebooktwittergoogle_pluslinkedinmail

This week the Q3-season began. There were report from Fortnox, Heliospectra and Recyctec. Fortnox showed strong growth both in terms of turnover and in terms of profit. Heliospectra had a strong order intake and moves in the right direction with rising turnover and falling loss. Recyctec announced a few days before the report that the company will run out of cash in December. Recyctec also announced a revision of their prior financial targets. Both Heliospectra and Recyctec rose slightly after their reports. Fortnox are up 9 %. Dignitana is quite another story… Continue reading

Recyctec

Investor confidence on a late Friday afternoon

Facebooktwittergoogle_pluslinkedinmailFacebooktwittergoogle_pluslinkedinmail

The first Friday of June was odd. There were two announcements in the mid-afternoon, affecting share prices. Both said something on investor confidence. They probably came out late in order to minimize the effect on the share price. BrainCool announced the outcome of the preferential rights issue at 14:30. Shortly after Recyctec lost 15 % of its value due to lack of investor confidence following an announcement half an hour later. Let’s go by alphabetic order today. Continue reading

A1M share price

A1M Pharma – an unusual share price development

Facebooktwittergoogle_pluslinkedinmailFacebooktwittergoogle_pluslinkedinmail

When A1M Pharma announced an issue February 7th the share market acted as always and started a steep slide towards the issue price of 0.75 SEK. The day before the announcement, the share closed at 1.97. Three days later, it had dropped to half the price – 0.98 SEK. So far, everything was normal. Usually the share price then would move a little closer to the issue price ending perhaps with a premium of 5-25 % for taking the risk. What we see in A1M is something quite different. Continue reading

Recyctec

Guarantors saves Recyctec’s issue

Facebooktwittergoogle_pluslinkedinmailFacebooktwittergoogle_pluslinkedinmail

Well, Recyctec announced the outcome of the issue in February this week. The preferential rights issue had a 100 percent guarantee, which came into use since current shareholders subscribed only 44 % and other investors accounted for 26 %. The guarantors covered the rest – 30 %.

The outcome came as a surprise to me since the prospects of the company are good. There are no known competitors, the company is riding on the huge Green Wave, Recyctec have distribution agreements with a number of distributors, and this issue ought to bring the company to break even in 2017. Then why does only 44 % of the current shareholders have the faith in the company and are willing to subscribe? Continue reading

Recyctec

Recyctec – the last issue?

Facebooktwittergoogle_pluslinkedinmailFacebooktwittergoogle_pluslinkedinmail

Prolonging the list of issues during 2016, Recyctec began 2017 with an announcement of a preferential rights issue on January 13th. During 2016, the company have muddled its way through. Production problems during summer, which turned over plans for a break through and breakeven, has made things difficult for Recyctec. This even after private placements in March and June and a 10 MSEK loan in December. Hopefully, this issue will provide enough funding to allow the company to focus on sales. The financial goals are profits in 2017 and a turnover of more than 100 MSEK with a margin of more than 30% in 2020. Probably this is the last issue from Recyctec. Continue reading

Heliospectra

Heliospectra’s issue completed

Facebooktwittergoogle_pluslinkedinmailFacebooktwittergoogle_pluslinkedinmail

Heliospectra completed the announced issue in the first half of December. There was a 118 % subscription rate. The total amount is 107 MSEK, with 91 MSEK from the regular subscription and 16 MSEK from the oversubscription. According the decision from extra general meeting, shares for another 4 MSEK could have been issued if more investors have subscribed. Continue reading

CybAero

CybAero issue complete

Facebooktwittergoogle_pluslinkedinmailFacebooktwittergoogle_pluslinkedinmail

Well, the CybAero issue is complete. The subscription period ended on the 4th. On the 10th the result came: current investors subscribed for a little less than 50 %, outsides subscribed for 2 % and guarantors covered the remaining 48 %. In other words, the issue was far from fully subscribed and the amount raised is only 90 % of the amount planned. Continue reading

Recyctec

Recyctec almost there

Facebooktwittergoogle_pluslinkedinmailFacebooktwittergoogle_pluslinkedinmail

The past months, Recyctec have delivered a steady stream of news, some financial some on business development. On several occasions, I have mentioned Recyctec, and I thought it to be the right time, here halfway through 2016, to sum up the development of the company. It is no secret that I see the present share price far from a fair valuation of the company. On the other hand, it is true that the delays during last autumn did put strings on the company. Continue reading

Portfolio overview Q317

Almost successful issues

Facebooktwittergoogle_pluslinkedinmailFacebooktwittergoogle_pluslinkedinmail

The past two post I have focused on issues and IPO. This again will be the topic but from a different angel since A1M Pharma completed their issue this week and BrainCool announced a very peculiar form of private placement. Some issues are at best almost successful issues, which A1M Pharma is an example of. And of course there is the farce of the week: the postponed listing of lauritz.com. That wasn’t even ‘almost successful’ but straight out unsuccessful and made the laugh of the month. Continue reading